Clinical Remission in a 72-Year-Old Patient with a Massive Primary Cutaneous Peripheral T-Cell Lymphoma-NOS of the Eyelid, Following Combination Chemotherapy with Etoposide Plus COP.
chemotherapy
elderly patient
eyelid
primary cutaneous T-cell lymphoma
Journal
Diagnostics (Basel, Switzerland)
ISSN: 2075-4418
Titre abrégé: Diagnostics (Basel)
Pays: Switzerland
ID NLM: 101658402
Informations de publication
Date de publication:
24 Aug 2020
24 Aug 2020
Historique:
received:
25
07
2020
revised:
14
08
2020
accepted:
16
08
2020
entrez:
28
8
2020
pubmed:
28
8
2020
medline:
28
8
2020
Statut:
epublish
Résumé
Peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) is the rarest subtype of primary cutaneous lymphoma, accounting for approximately 2% of cutaneous lymphomas. The rarity of primary cutaneous PTCL-NOS means that there is a paucity of data regarding clinical and histopathological features and its clinical course. This malignancy is an aggressive and life-threatening hematological malignancy that often presents mimicking other less severe plaque-like skin conditions. Due to the nonspecific nature of these lesions, CD4-positive cutaneous T-cell lymphoma (CTCL) is often misdiagnosed as either mycosis fungoides or Sezary syndrome. We describe a patient who presented with a large tumoral mass in the right frontal area, with involvement of the right upper eyelid and the ocular globe, causing loss of vision greatly impacting the quality of life. Biopsy revealed primary cutaneous PTCL-NOS, treated successfully with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) plus etoposide combination chemotherapy. As elderly patients are indicated to receive attenuated doses of chemotherapy, CHOP-based regimens represent viable options.
Identifiants
pubmed: 32847118
pii: diagnostics10090629
doi: 10.3390/diagnostics10090629
pmc: PMC7555261
pii:
doi:
Types de publication
Case Reports
Langues
eng
Références
J Clin Med. 2020 Jan 20;9(1):
pubmed: 31968576
J Dermatol Sci. 2020 Mar;97(3):187-193
pubmed: 32033869
Med Pharm Rep. 2019 Oct;92(4):421-426
pubmed: 31750446
Yale J Biol Med. 2020 Mar 27;93(1):111-121
pubmed: 32226341
Hum Pathol. 2016 Jul;53:192-4
pubmed: 27016488
Front Oncol. 2019 Sep 10;9:892
pubmed: 31552193
Blood. 2019 Apr 18;133(16):1703-1714
pubmed: 30635287
Cancer Control. 2007 Apr;14(2):112-23
pubmed: 17387296
J Am Acad Dermatol. 2014 Feb;70(2):205.e1-16; quiz 221-2
pubmed: 24438969
Crit Rev Clin Lab Sci. 2018 Mar;55(2):102-114
pubmed: 29316828
Am J Hematol. 2019 Aug;94(8):929-946
pubmed: 31119775
Blood Res. 2017 Dec;52(4):270-275
pubmed: 29333403
Cytometry B Clin Cytom. 2019 Mar;96(2):116-127
pubmed: 30350336
Histopathology. 2016 Jun;68(7):1099-108
pubmed: 26426838
Am J Dermatopathol. 2015 Nov;37(11):822-33
pubmed: 26485239
Semin Hematol. 2014 Jan;51(1):17-24
pubmed: 24468312
Am J Clin Dermatol. 2016 Feb;17(1):71-7
pubmed: 26386881
J Clin Med. 2020 Jul 28;9(8):
pubmed: 32731502
Curr Hematol Malig Rep. 2016 Dec;11(6):492-503
pubmed: 27995419
Front Oncol. 2020 Jan 22;9:1558
pubmed: 32039026
Lancet Haematol. 2020 Apr;7(4):e284-e294
pubmed: 32105608
Semin Cutan Med Surg. 2018 Mar;37(1):24-29
pubmed: 29719017
Diagn Pathol. 2019 Oct 22;14(1):115
pubmed: 31640798
Pol J Pathol. 2009;60(1):43-8
pubmed: 19670703
J Cutan Pathol. 2006 Feb;33 Suppl 1:18-26
pubmed: 16412209
Am J Hematol. 2017 Oct;92(10):1085-1102
pubmed: 28872191
Eur J Dermatol. 2015 Apr;25(2):210
pubmed: 25895431
Cancer Treat Res. 2019;176:1-29
pubmed: 30596211
Expert Rev Hematol. 2017 Mar;10(3):239-249
pubmed: 28133975
Onco Targets Ther. 2016 Feb 22;9:863-8
pubmed: 26955284
Ann Hematol. 2019 Aug;98(8):1961-1972
pubmed: 31065733
CA Cancer J Clin. 2020 Jan;70(1):47-70
pubmed: 31815293
Semin Diagn Pathol. 2017 Jan;34(1):22-35
pubmed: 27993440
Am J Hematol. 2014 Aug;89(8):837-51
pubmed: 25042790
Hematol Oncol. 2020 Feb;38(1):51-58
pubmed: 31872891
Expert Rev Hematol. 2019 Oct;12(10):833-843
pubmed: 31365276